Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 173.03M
March 31, 2026 202.77M
December 31, 2025 235.70M
September 30, 2025 124.39M
June 30, 2025 146.44M
March 31, 2025 172.50M
December 31, 2024 196.33M
September 30, 2024 219.44M
June 30, 2024 121.52M
March 31, 2024 143.04M
December 31, 2023 162.32M
September 30, 2023 168.25M
June 30, 2023 105.18M
March 31, 2023 114.78M
December 31, 2022 125.88M
September 30, 2022 134.08M
June 30, 2022 142.44M
March 31, 2022 151.80M
December 31, 2021 161.17M
September 30, 2021 170.81M
June 30, 2021 180.67M
March 31, 2021 192.71M
December 31, 2020 82.19M
September 30, 2020 94.34M
June 30, 2020 99.61M
Date Value
March 31, 2020 104.99M
December 31, 2019 121.77M
September 30, 2019 106.28M
June 30, 2019 111.73M
March 31, 2019 105.18M
December 31, 2018 110.83M
September 30, 2018 112.05M
June 30, 2018 74.76M
March 31, 2018 84.98M
December 31, 2017 94.35M
September 30, 2017 53.29M
June 30, 2017 61.13M
March 31, 2017 7.771M
December 31, 2016 13.37M
September 30, 2016 26.95M
June 30, 2016 35.07M
March 31, 2016 37.09M
December 31, 2015 40.98M
September 30, 2015 49.91M
June 30, 2015 43.38M
March 31, 2015 49.89M
December 31, 2014 57.29M
September 30, 2014 43.07M
June 30, 2014 46.44M
March 31, 2014 49.62M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 4.882B
Insmed, Inc. 1.160B
United Therapeutics Corp. 2.662B
Vertex Pharmaceuticals, Inc. 7.863B
SELLAS Life Sciences Group, Inc. 138.44M